About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
IMGN - ImmunoGen| Previous Close | $5.70 | Open | |
| Volume | Market Cap | 276.63M | |
| Yield | Last Dividend |
| ImmunoGen Beats Expectations and Fuels O... | 02/14/20 |
| Cost-cutting led to a surprise profit, and the company outlined the path ahead for its pipeline treatment for ovarian cancer. | |
| ImmunoGen (IMGN) Q4 Earnings and Revenue... | 02/14/20 |
| ImmunoGen (IMGN) delivered earnings and revenue surprises of 160.00% and 53.43%, respectively, for the quarter ended December 2019. Do the numbers hol... | |
| ImmunoGen Inc (IMGN): Q4 2019 Earnings S... | 02/14/20 |
| ??? ImmunoGen Inc. (NASDAQ: IMGN) reported its fourth-quarter 2019 earnings of $0.03 per share vs $0.05 per share loss expected. ??? Revenue jumped th... | |
| ImmunoGen Reports Recent Progress and 20... | 02/14/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and 2019 Financial Results | |
| ImmunoGen Announces Webcasts of Presenta... | 02/06/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences | |
| ImmunoGen Announces Conference Call to D... | 01/30/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its 2019 Operating Results | |
| ImmunoGen Announces Closing of Public Of... | 01/27/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters??? Option to Purchase Additional Sha... | |
| ImmunoGen down 10% premarket on pricing ... | 01/23/20 |
| ImmunoGen (NASDAQ:IMGN) has priced its public offering of 21,325,000 common shares at $4.25 per share, for expected gross proceeds of $90.6M. Underwri... | |
| ImmunoGen Announces Pricing of Public Of... | 01/22/20 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Pricing of Public Offering of Common Stock | |
| ImmunoGen : Announces Inducement Grant U... | 12/31/19 |
| ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that on December 23, 2019 the... | |
| ImmunoGen (IMGN) Looks Good: Stock Adds ... | 12/19/19 |
| ImmunoGen (IMGN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes. | |
| ImmunoGen Lead Drug Gets Nod for Acceler... | 12/18/19 |
| FDA approves a new pivotal study to support accelerated approval pathway for ImmunoGen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine. S... | |
| 8 Stocks To Watch: ABBV, AMD, AXSM, IMGN... | 12/16/19 |
| Stocks Analysis by Harry Boxer covering: Advanced Micro Devices Inc, ImmunoGen Inc, SeaChange International Inc, Maxar Technologies Inc. Read Harry Bo... | |
| ImmunoGen Presents Updated Findings from... | 12/09/19 |
| WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Updated Findings from Phase 1 Study of IMGN632 at ASH Annual Meeting | |
| How Many ImmunoGen, Inc. (NASDAQ:IMGN) S... | 11/05/19 |
| A look at the shareholders of ImmunoGen, Inc. (NASDAQ:IMGN) can tell us which group is most powerful. Insiders often??? | |
| ImmunoGen (IMGN) Q3 Earnings & Sales Bea... | 11/04/19 |
| ImmunoGen (IMGN) reports narrower-than-expected third-quarter loss and beats revenue estimates. The company is set to initiate the FDA recommended pha... | |
| What 3 top investment firms are betting ... | 10/03/19 |
| The explosion of streaming-video services is giving rise to new areas of media investments for venture capitalists and other early-stage investors. Bu... | |
| Did ImmunoGen, Inc. (NASDAQ:IMGN) Inside... | 09/30/19 |
| It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be??? | |
| ImmunoGen (IMGN) Up 18.8% Since Last Ear... | 09/01/19 |
| ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| ImmunoGen (IMGN) Stock Down Despite Q2 E... | 08/05/19 |
| ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019... | |
| ImmunoGen EPS beats by $0.04, beats on r... | 08/02/19 |
| ImmunoGen (IMGN): Q2 GAAP EPS of -$0.29 beats by $0.04. Revenue of $15.54M (+67.3% Y/Y) beats by $5.18M. Press Release | |
| Earnings Preview: ImmunoGen (IMGN) Q2 Ea... | 07/26/19 |
| ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with... | |
| ImmunoGen axes 75% of staff to fund new ... | 06/28/19 |
| After its Phase 3 trial failed, ImmunoGen has opted to continue testing its ovarian cancer drug in a subgroup of patients with high rates of a protein... | |
| Why Is ImmunoGen (IMGN) Down 26% Since L... | 06/02/19 |
| ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| ImmunoGen Plunges as FDA Recommends New ... | 05/16/19 |
| FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine. | |
| Why Immunogen Was Down by More than 30% ... | 05/16/19 |
| Why Did Immunogen Stock Crash on May 15?Recent regulatory updateOn May 15, Immunogen (IMGN) issued a press release announcing the FDA???s recommendati... | |
| The Daily Biotech Pulse: FDA Nod For Roc... | 05/16/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 15) A... | |
| Why The Children's Place, Agilent Techno... | 05/15/19 |
| Despite a solid gain in the market, these companies struggled. | |
| ImmunoGen, Solid Biosciences and Insys l... | 05/15/19 |
| Shares of ImmunoGen Inc. led biotech???s losers on Wednesday, falling 38% in intraday trade after the company disclosed that the U.S. Food and Drug??? | |
| Why ImmunoGen Shares Are Crashing Today | 05/15/19 |
| Disappointing news from the FDA means that the biotech company is further from potentially winning approval for its lead drug candidate. | |
| Date | 2020-02-14 (BMO) | Est. (EPS/Rev.) | ($0.05)/ 29.33M |
| Actual (EPS/Rev.) | $0.03/ $44.86 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Option Attack | James Callyway | 61.00 % | Subscribe |
| Burdeshaw Investing | Matthew Burdeshaw | 55.00 % | Subscribe |
| Tech and Bio Swing Trades | Matthew Burdeshaw | 46.00 % | Subscribe |
| Long Only Biotech/Pharma | Biotech Buys | 33.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
